A student-run resource for reliable reports on the latest law and technology news

Written Description Problems of the Monoclonal Antibody Patents after Centocor v. Abbott 

Written By: Hyeongsu Park - Edited By: Kendra Albert

The market for therapeutic antibodies is projected to reach hundreds of billion dollars within the next several years. In Centocor v. Abbott, the Court of Appeals for the Federal Circuit (“Federal Circuit”) held that a patentee cannot claim an antibody unless the specification describes it, even if he/she fully characterizes the antigen, and the court vacated a $1.67 billion jury verdict, the largest patent infringement award in U.S. history.

Read More...

Posted On Mar - 13 - 2014 Comments Off READ FULL POST
  • RSS
  • Facebook
  • Twitter
  • GooglePlay
Television

District Court Holds

By Anne Woodworth – Edited by Henry Thomas Order: Fox Television ...

Neiman Marcus

Data Breach Victims,

By Brittany Doyle – Edited by Ariane Moss Remijas v. Neiman ...

Magnifying Glass

How Far Can Law Enfo

By Kasey Wang – Edited by Ariane Moss State v. Rindfleisch, ...

Russia & China Cropped

Russia’s “Right

By Brittany Doyle - Edited by Ken Winterbottom The legislatures in ...

Avvo Logo Cropped

Washington Appeals C

By Leonidas Angelakos – Edited by Olga Slobodyanyuk Thomson v. Doe, ...